Fourth Quarter 2025 Supplemental Information March 4, 2026 Disclaimers Forward looking statements This presentation contains historical information, as well as forward-looking statements (within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) that involve known and unknown risks and relate to, among other things, future events, projections, financial guidance, legislative or regulatory developments ...

Summary of Addus HomeCare FY Conference Call (March 03, 2026) Company Overview - **Company**: Addus HomeCare (NasdaqGS:ADUS) - **Industry**: Personal Care and Home Health Services - **Revenue**: Over $1.5 billion with a bottom line margin between 12% and 13% [4][5] Key Points and Arguments Management and Business Strategy - The management team is described as high quality with a strong focus on maintaining a pristine balance sheet [1] - The company has transitioned from a pure play personal care company to a more diversified service provider, including clinical services [4] - The vision was to achieve double-digit margins with the right scale and growth profile, which has been realized over time [4] Medicaid and Pricing Dynamics - Concerns about Medicaid fraud and pricing dynamics were discussed, with a focus on state-specific rate increases [6][8] - Texas provided a nearly 10% rate increase effective September 2025, while Illinois has been consistent with annual increases [8][9] - New Mexico is expected to provide a 4% to 5% rate increase later in the year [10] Compliance and Quality Assurance - The company has invested heavily in compliance, with robust training and supervisory processes for caregivers [17][18] - Despite industry scrutiny, Addus has not seen changes in state audits and welcomes more scrutiny as a high-quality provider [18][21] Labor Market and Demand - The company has not observed significant impacts from immigration or Medicaid cuts on labor availability or customer demand [22][24] - Hiring remains a key focus, with expectations of improved census numbers as the economy shifts [47] Acquisition Strategy - The Gentiva acquisition, closed in December 2024, added $280 million in annualized revenue and positioned Addus as the largest provider in Texas [28][29] - The company is open to smaller tuck-in acquisitions and is monitoring the market for larger personal care assets expected to be available later in the year [66][67] Technology and Operational Improvements - A caregiver app was rolled out to improve fill rates, resulting in an increase from low 80% to upper 80% in Illinois [33][36] - The app allows caregivers to manage their schedules and pick up extra shifts, enhancing operational efficiency [34] Hospice Business Performance - The hospice segment has shown strong growth post-COVID, with consistent admission growth and improved average daily census (ADC) [51][54] - The company has made strategic changes in leadership and sales to enhance performance in hospice services [54] Market Outlook - The company anticipates continued top-line growth and margin expansion, with hospice expected to see upper single-digit organic growth in the long term [71][73] - There is optimism about the potential for positive year-over-year results in census numbers as operational improvements take effect [48] Additional Important Insights - The company is actively engaged in government relations across multiple states to navigate regulatory environments [25][26] - There is a focus on maintaining a clean balance sheet to capitalize on future acquisition opportunities [66] - The management is cautious about the home health market, preferring to focus on personal care and hospice segments due to the current reimbursement environment [60][61] This summary encapsulates the key discussions and insights from the Addus HomeCare FY Conference Call, highlighting the company's strategic direction, market dynamics, and operational performance.

Financial Data and Key Metrics Changes - For Q4 2025, total company revenue was $3.6 billion, representing a 29% increase year-over-year [25] - Full year 2025 total revenue reached $12.9 billion, reflecting a 28% growth from 2024 [28] - Adjusted EBITDA for Q4 was $184 million, a 41% increase compared to Q4 2024, while full year adjusted EBITDA was $618 million, up 34% year-over-year [29][11] - The adjusted EBITDA margin for the company was 4.8%, a 20 basis point increase from 2024 [11] Business Line Data and Key Metrics Changes - Pharmacy Solutions segment revenue for Q4 was $3.2 billion, achieving 32% year-over-year growth, while full year revenue was $11.4 billion, up 31% [25][28] - Provider Services segment revenue in Q4 was $394 million, representing a 13% increase year-over-year, with home healthcare revenue growing 19% to $217 million [27][20] - In the Pharmacy Solutions segment, infusion and specialty revenue was $2.6 billion, growing 43% year-over-year, while home and community pharmacy revenue declined 1% to $593 million [26] Market Data and Key Metrics Changes - The average daily census in home healthcare grew 15% to almost 35,000 in Q4, driven by strong quality metrics and strategic acquisitions [21] - Specialty and infusion script growth was 30% year-over-year in Q4, with total pharmacy script volume at 10.8 million [17] Company Strategy and Development Direction - The company plans to divest the community living business to streamline operations and focus on core patient populations [6] - The acquisition of Amedisys and LHC Home Health Assets is expected to enhance the company's home health capabilities, contributing approximately $30 million to adjusted EBITDA in 2026 [13][35] - The company aims to build a unique and scaled home and community healthcare platform, emphasizing quality outcomes and operational best practices [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future of home health and hospice, anticipating a strong growth trajectory over the next 5 to 10 years [50] - The company expects total revenue growth of approximately 14% year-over-year for 2026, with adjusted EBITDA growth of about 25% [13][34] - Management highlighted the importance of executing sales investments and operational efficiencies to drive volume growth and margin expansion [38][39] Other Important Information - The company achieved a leverage ratio of 2.99 times as of December 31, 2025, down from 4.16 times in 2024, indicating improved financial health [32] - The company is initiating a foundation to support community and patient activities, reflecting its commitment to social responsibility [14] Q&A Session Summary Question: Variability in 2026 Outlook - Management noted consistency in Q1 and emphasized the importance of executing strategies to drive volume growth across businesses [37] Question: LDD Introductions and Landscape - Management confirmed expectations for 16-20 new LDD introductions over the next 12-18 months, with a focus on expanding capabilities [40][41] Question: EBITDA and Margins for Segments - Management indicated broad-based margin expansion is expected due to operational efficiencies and favorable product mix [45][46] Question: Home Health Rate Environment - Management expressed optimism about home health rates, projecting a flat baseline with potential for future increases [50] Question: Specialty Drug Launches and Margins - Management highlighted the multifactorial growth in specialty pharmacy, including brand LDDs and generic conversions, which improve margins [55] Question: Amedisys Asset Margins - Management acknowledged the lower margin profile of the Amedisys assets but expressed confidence in improving margins through integration [61][62] Question: Pharmacy Revenue Guidance Components - Management outlined expected revenue headwinds from IRA impacts and generic conversions but anticipated strong growth across pharmacy businesses [70][71] Question: Infusion Business Update - Management reported double-digit growth in the infusion business and plans for significant investments to enhance capabilities [73][75]

Financial Data and Key Metrics Changes - The company reported full-year consolidated revenue of $947.7 million, an increase of $252.5 million, or 36.3% year-over-year [8] - Adjusted EBITDA for the full year was $72.5 million, up $19.2 million, or 36% compared to the previous year [8] - Adjusted earnings per share for the full year reached $1.18, exceeding the midpoint of the updated annual guidance of $1.16 [7][8] Business Line Data and Key Metrics Changes - In the home health and hospice segment, Q4 revenue was $233.3 million, an increase of $91.3 million, or 64.3% year-over-year, with adjusted EBITDA of $33.7 million, up $12.4 million, or 58.2% [14] - The senior living segment saw full-year revenue improve to $215 million, an increase of $39.2 million, or 22.3% over the prior year [17] - Q4 senior living segment revenue was $56.1 million, an increase of $9.2 million, or 19.6% year-over-year [17] Market Data and Key Metrics Changes - The average daily census in hospice grew to 5,060, a 46.9% increase over the prior year quarter [16] - Same-store Medicare admissions in home health grew by 8.2%, with a 3.7% increase in Medicare revenue per episode [15] - All-store occupancy in senior living rose by 200 basis points to 80.6%, with same-store occupancy increasing by 250 basis points to 82.1% [18] Company Strategy and Development Direction - The company aims to optimize performance and drive operational excellence while remaining open to selective acquisitions [10] - Focus areas include leadership development, clinical excellence, employee experience, margin improvement, and growth [9] - The company plans to continue expanding its senior living business, capitalizing on the upward trajectory of occupancy and revenue [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the underlying trajectory of the business despite reimbursement headwinds [15] - The company anticipates a full-year revenue guidance of $1.13 billion to $1.17 billion for 2026, reflecting a 22.4% increase at the midpoint [12] - Management highlighted the importance of local leadership and community engagement in driving growth and clinical outcomes [59] Other Important Information - The company completed the acquisition of Signature Healthcare at Home and over 50 locations from UnitedHealth and Amedisys, enhancing its operational reach [8][9] - The balance sheet remains strong, with a net debt to adjusted EBITDA ratio of 1.7 times, well below the covenant limit [24] Q&A Session Summary Question: Is the guidance conservative due to the integration of AMED LHCG? - Management confirmed that the guidance reflects expected initial noise during the transition of operations [32] Question: How do joint ventures perform compared to non-JV agencies? - Management stated that joint ventures are treated like any Pennant business, focusing on local leadership and collaboration with health system partners [34] Question: What are the expectations for the ramp-up of Amedisys UNH assets? - Management noted similarities with previous acquisitions and expressed confidence in local leaders and teams to facilitate a smooth transition [41][42] Question: What is the outlook for same-store revenue growth in home health and hospice? - Management indicated a projected 7% increase in same-store home health and hospice revenue for 2026 [53] Question: What is the competitive backdrop in the hospice segment? - Management highlighted a normalization in growth trends and the opportunity presented by the aging population [80]

Core Insights - Chemed Corporation reported its fourth quarter financial results for 2025, highlighting mixed performance across its segments, VITAS and Roto-Rooter, with VITAS showing slight revenue growth while Roto-Rooter experienced a decline in revenue [1][2]. VITAS Segment Performance - VITAS net revenue reached $418.8 million in Q4 2025, marking a 1.9% increase from the previous year, driven by a 1.3% rise in days-of-care and a 2.2% increase in Medicare reimbursement rates [4]. - Total VITAS admissions rose by 6.0% in Q4 2025 compared to Q4 2024, indicating a positive trend in patient intake [5]. - The average revenue per patient per day was $208.01, an increase of 86 basis points year-over-year, with routine home care and high acuity care averaging $187.19 and $1,153.55, respectively [7]. - The gross margin for VITAS, excluding Medicare Cap, was 27.3%, down 150 basis points from the same period in 2024 [8]. Roto-Rooter Segment Performance - Roto-Rooter generated $220.6 million in revenue for Q4 2025, a decrease of 3.7% compared to the prior year, with commercial revenue slightly increasing by 1.6% while residential revenue fell by 3.1% [11][12]. - The gross margin for Roto-Rooter was 49.8%, down from 51.3% in the previous year, with selling, general, and administrative expenses rising by 10.5% [13]. - Adjusted EBITDA for Roto-Rooter was $47.5 million, reflecting a 21.1% decline year-over-year, with an adjusted EBITDA margin of 21.5%, down 477 basis points [14]. Consolidated Financials - Chemed's total revenue for Q4 2025 was $639.3 million, essentially flat compared to Q4 2024, with GAAP diluted EPS at $5.48, a decrease of 9.0% [8]. - The company reported a net income of $76.8 million for Q4 2025, down 0.6% from the previous year, while adjusted EBITDA, excluding Medicare Cap, was $91.6 million, a decline of 1.7% [9]. Guidance for 2026 - VITAS expects revenue growth of 5.5% to 6.5% in 2026, with an estimated average daily census increase of 3.5% to 4.0% [20]. - Roto-Rooter is projected to achieve revenue growth of 3.0% to 3.5% in 2026, with an adjusted EBITDA margin forecasted between 22.5% and 23.0% [21]. - The company anticipates full-year 2026 earnings per diluted share to be in the range of $23.25 to $24.25, compared to $21.55 in 2025 [21].

Financial Performance - In Q4, revenue increased by 9.9% to $1.5 billion, and adjusted EBITDA rose by 15.9% to $335.6 million, driven by 5.3% discharge growth and a 4.1% increase in net revenue per discharge [1][5] - For the full year 2025, revenue grew by 10.5%, with EBITDA increasing by 14.9%, supported by operating leverage and disciplined expense management [3][5] - Adjusted free cash flow for the full year was $818 million, reflecting an 18.5% increase [9] Labor and Operational Efficiency - Premium labor costs decreased significantly, down more than $21 million year-over-year in 2025, with Q4 premium labor at $23.8 million, the lowest since Q1 2021 [2][5][7] - The company added approximately 300 same-store registered nurses (RNs) during 2025, contributing to improved operational efficiency [7] Capacity Expansion and Growth Strategy - Management plans to add 517 beds in 2025 through new hospitals and expansions, with ongoing investments expected to meet a growing target demographic [12] - A new 24-bed small-format hospital prototype is set to launch in 2027 as part of a hub-and-spoke strategy [13] 2026 Guidance - For 2026, management guided net revenue of $6.365–6.465 billion, adjusted EBITDA of $1.34–1.38 billion, and adjusted EPS of $5.81–6.10, with a leverage target of approximately 1.83x [4][18] Regulatory and Payer Dynamics - The company reported a 93% affirmation rate for its Alabama hospitals under the RCD model, indicating effective engagement with CMS [16] - Management expressed concerns about challenges with a national Medicare Advantage payer, which affected conversion rates despite referral growth [20]

Financial Data and Key Metrics Changes - The company reported revenues of $229 million for Q3 2025, an increase of $48.4 million, or 26.8% year-over-year [5] - Adjusted EBITDA was $17.3 million, up $2.2 million, or 14.5% compared to the prior year quarter [5] - Adjusted EPS increased to $0.30, reflecting a $0.04 increase, or 15.4% year-over-year [5] - Full-year revenue guidance was raised to between $911.4 million and $948.6 million, with adjusted EBITDA expected between $70.9 million and $73.8 million [10][25] Business Line Data and Key Metrics Changes - Home Health and Hospice segment revenue reached $173.6 million, a 27.9% increase, with adjusted EBITDA of $26.8 million, up 22.7% [12] - Senior Living segment revenue was $55.5 million, up 23.2% year-over-year, with adjusted EBITDA increasing 26.2% [15] - Same-store occupancy in senior living reached 81.8%, with all-store occupancy at 80.9% [15] Market Data and Key Metrics Changes - The average CMS reported star rating for home health was 4.1, compared to the industry average of three stars [12] - Potentially preventable hospitalizations decreased to 8.4%, below the national average of 9.9% [12] - Hospice quality composite score improved to 97%, exceeding the national average of 92% [12] Company Strategy and Development Direction - The company is focused on integrating the recently acquired UnitedHealth Amedisys operations and enhancing local leadership [5][33] - There is a strong emphasis on empowering local clinical leaders to drive operational success and improve clinical outcomes [9][12] - The company plans to continue pursuing acquisition opportunities in senior living and home health, maintaining a disciplined approach [23][60] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term value of home health services despite current regulatory uncertainties [19] - The company anticipates some lumpiness in results due to integration efforts but expects significant long-term potential from recent acquisitions [6][10] - Management highlighted the importance of local leadership and community engagement in driving operational success [9][48] Other Important Information - The company closed on a $100 million term loan to enhance balance sheet capacity [24] - The acquisition of UnitedHealth Amedisys included 54 locations with trailing 12-month revenues of $189.3 million [21] - The company is actively advocating against proposed regulatory changes that could negatively impact the industry [9][18] Q&A Session Summary Question: What are the top priorities for integration after the Amedisys transaction? - The focus is on identifying and elevating leaders, ensuring exceptional support for agencies, and developing a joint venture with the University of Tennessee [33][34] Question: How should we think about margins in senior living going forward? - As occupancy increases, there is an expectation for improved margins, with a focus on operational efficiency and revenue quality [38] Question: What dynamics are affecting margin guidance? - NCI growth and elevated G&A expenses are impacting EBITDA margins, with adjustments made for these factors [40][41] Question: What is driving the increase in hospice length of stay? - The increase reflects a return to pre-pandemic levels and improved identification of appropriate patients for hospice services [42][43] Question: How is the internal reception of the Amedisys assets? - Employees have shown excitement and commitment, with minimal turnover and strong performance during the transition [46][49] Question: What is the competitive landscape for senior living acquisitions? - There is increased activity in the senior living space, with a mix of opportunities within the company's target range [60][62]

Q3 2025 Performance Highlights - Consolidated net service revenue increased by 3.9% year-over-year to $263.6 million[19, 20] - Adjusted EBITDA grew by 10.2% year-over-year to $27.0 million, with an Adjusted EBITDA margin of 10.2%[19, 20] - Net income attributable to Enhabit, Inc was $11.1 million, a 110.1% increase compared to the previous year[19, 20] - Adjusted diluted EPS was $0.17, a 466.7% increase compared to the previous year[19, 20] Home Health Segment - Home health net service revenue was $200.5 million, a decrease of 0.2% year-over-year[19, 20] - Total admissions increased 3.6% year-over-year[18, 68] - Medicare admissions decreased by 5.1% year-over-year, while non-Medicare admissions increased by 10.4%[19, 68] - Cost per patient day improved by 2.1% year-over-year[19, 68] Hospice Segment - Hospice net service revenue increased by 20.0% year-over-year to $63.1 million[19, 20] - Adjusted EBITDA increased 72.0% year-over-year[19] - Average daily census grew by 12.6% year-over-year[18, 38] - Cost per patient day improved by 3.1% year-over-year[19, 44] Balance Sheet and Guidance - Reduced bank debt by $15.0 million in Q3, exiting with a 3.9x leverage ratio[19] - Total debt reduced by $100 million since Q4 2023[51] - Updated 2025 net service revenue guidance to $1.058 billion to $1.063 billion[56]

Financial Data and Key Metrics Changes - The company reported Q2 2025 revenue of $219.5 million, an increase of $50.8 million or 30.1% year-over-year, and adjusted EBITDA of $16.4 million, up $3.2 million or 24.5% from the prior year quarter [7][32][10] - GAAP diluted earnings per share for the quarter was $0.20, while adjusted diluted earnings per share was $0.27 [32] Business Line Data and Key Metrics Changes - In the Home Health and Hospice segment, revenue reached $166 million, an increase of $40.7 million or 32.5%, with adjusted EBITDA of $25.5 million, up $5.9 million or 29.9% year-over-year [15] - Hospice revenue was $73.8 million, an increase of $14.4 million or 24.3%, with hospice admissions up 14.7% and average daily census up 21.4% [16] - Home health revenue grew to $79.2 million, an increase of $17.6 million or 28.5%, with total home health admissions increasing 26.1% [19] - Senior Living segment revenue improved to $53.5 million, an increase of $10 million or 23.1%, with same store occupancy exceeding 80% [24][26] Market Data and Key Metrics Changes - The company anticipates full-year revenue in the range of $852.8 million to $887.6 million, with adjusted earnings per share expected between $1.09 and $1.15 [13][32] - The proposed 2026 Home Health Rule suggests a net reduction of 6.4% in aggregate payments to home health agencies, which could impact the company's revenue [21][22] Company Strategy and Development Direction - The company is focused on leadership development, clinical excellence, employee engagement, margin improvement, and growth as key focus areas for continuous improvement [7] - The acquisition of divested assets from Amedisys and UnitedHealth Group is seen as a significant opportunity to expand operations in attractive markets, particularly in Tennessee, Alabama, and Georgia [12][29] - The company is committed to adapting its operations to the changing regulatory environment and believes in the essential role of home health services in the healthcare continuum [23][24] Management's Comments on Operating Environment and Future Outlook - Management expressed concerns about the proposed home health rule, stating it could negatively affect access to care for vulnerable patients and increase overall healthcare spending [22][23] - Despite challenges, management remains optimistic about the company's growth trajectory, citing strong performance across various segments and a healthy balance sheet [10][13] Other Important Information - The company has a strong focus on operational efficiency and has implemented various initiatives to improve clinical quality and financial performance [20][24] - The company is actively preparing for the integration of newly acquired assets and has invested in leadership and operational training to ensure a smooth transition [58][70] Q&A Session Summary Question: Insights on the Tennessee market and payer landscape - Management highlighted the unique opportunities in the Tennessee market, emphasizing the potential for building a care continuum and the presence of quality providers [41][43] Question: Impact of proposed clawback on capitated relationships - Management acknowledged that adjustments from Medicare rate changes could affect both traditional and capitated contracts, but emphasized the company's diversified business model [46][48] Question: Sustainability of revenue per occupied bed in senior living - Management indicated that while they anticipate mid-single-digit growth in revenue per occupied bed, they are encouraged by recent occupancy growth [54][56] Question: Preparations for the Amedisys acquisition - Management detailed investments in leadership and resources to ensure a successful transition and operational efficiency post-acquisition [57][58] Question: Balancing M&A versus market share growth amid regulatory changes - Management expressed confidence that disruptions in the market could create opportunities for growth, emphasizing a strategic approach to acquisitions [59][62]

Financial Performance - Total net service revenue increased by 2.1% year-over-year to $266.1 million in Q2 2025[20] - Hospice net service revenue increased significantly by 19.4% year-over-year to $60.2 million[20] - Net income attributable to Enhabit, Inc was $5.2 million, a substantial increase compared to a loss of $0.2 million in Q2 2024[19, 20] - Adjusted EBITDA increased by 6.7% year-over-year to $26.9 million, with an Adjusted EBITDA margin of 10.1%[19, 20] - Home health net service revenue decreased by 2.0% year-over-year to $205.9 million[19, 20] Operational Metrics - Home Health non-Medicare admissions increased by 5.2% year-over-year[18, 63] - Hospice average daily census (ADC) grew by 12.3% year-over-year[18, 40] - Home Health Medicare ADC decreased by 3.4% compared to a 14.1% decline in the corresponding 2024 period[28] Debt and Liquidity - Bank debt was reduced by $10.0 million in Q2 2025, and is $70.0 million lower than Q1 2024[19] - Total debt decreased from $515.4 million at the end of 2024 to $479.3 million as of June 30, 2025[53] - Available liquidity was $113.5 million as of June 30, 2025[53, 55] Guidance - Updated 2025 net service revenue guidance to $1.06 billion to $1.073 billion[56]